Septerna Selects SEP-204 as Development Candidate and Reports Preclinical Data
Septerna selected SEP-204 as a development candidate for Graves' disease and TED and reported preclinical data at the 2026 American Thyroid Association Annual Meeting.
Septerna selected SEP-204 as a development candidate for Graves' disease and TED and reported preclinical data at the 2026 American Thyroid Association Annual Meeting.